Mitochondrial Trnaleu(Uur) May Cause an MERRF Syndrome

Total Page:16

File Type:pdf, Size:1020Kb

Mitochondrial Trnaleu(Uur) May Cause an MERRF Syndrome J7ournal ofNeurology, Neurosurgery, and Psychiatry 1996;61:47-51 47 The A to G transition at nt 3243 of the J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.61.1.47 on 1 July 1996. Downloaded from mitochondrial tRNALeu(uuR) may cause an MERRF syndrome Gian Maria Fabrizi, Elena Cardaioli, Gaetano Salvatore Grieco, Tiziana Cavallaro, Alessandro Malandrini, Letizia Manneschi, Maria Teresa Dotti, Antonio Federico, Giancarlo Guazzi Abstract Two distinct maternally inherited encephalo- Objective-To verify the phenotype to myopathies with ragged red fibres have been genotype correlations of mitochondrial recognised on clinical grounds: MERRF, DNA (mtDNA) related disorders in an which is characterised by myoclonic epilepsy, atypical maternally inherited encephalo- skeletal myopathy, neural deafness, and optic myopathy. atrophy,' and MELAS, which is defined by Methods-Neuroradiological, morpholog- stroke-like episodes in young age, episodic ical, biochemical, and molecular genetic headache and vomiting, seizures, dementia, analyses were performed on the affected lactic acidosis, skeletal myopathy, and short members of a pedigree harbouring the stature.2 Molecular genetic studies later con- heteroplasmic A to G transition at firmed the nosological distinction between the nucleotide 3243 of the mitochondrial two disorders, showing that MERRF is strictly tRNAI-u(UR), which is usually associated associated with two mutations of the mito- with the syndrome of mitochondrial chondrial tRNALYs at nucleotides 83443 and encephalomyopathy, lactic acidosis, and 8356,4 and MELAS with three point muta- stroke-like episodes (MELAS). tions of the mitochondrial tRNAIxu(UUR) at Results-The proband was affected by a nucleotides 3243, 3271, and 3291; the 3243 A fullblown syndrome of myoclonic to G transition (A3243G) is the most common epilepsy with ragged red fibres cause of MELAS.5 (MERRF), severe brain atrophy, and We discuss here the clinical, neuroradiolog- basal ganglia calcifications, without the ical, morphological, biochemical, and molecu- MRI T2 hyperintense focal lesions which lar genetic findings in the affected members of are pathognomonic of MELAS. Oligo- a clinically atypical pedigree harbouring the symptomatic relatives were variably heteroplasmic A3243G "MELAS" mutation. affected by lipomas, goitre, brain atro- phy, and basal ganglia calcifications. Muscle biopsies in the proband and his Patients and methods mother showed a MELAS-like pattern PEDIGREE ANALYSIS http://jnnp.bmj.com/ with cytochrome c oxidase hyperreactive Family member III-1 proband ragged red fibres and strongly succinate The proband, an 18 year old man, was the dehydrogenase reactive vessels. firstborn of non-consanguineous parents (fig Quantification of the A3243G mutation 1). Since the age of 5 years, he had had disclosed 78% and 70% of mutated mtDNA in the muscle of the severely affected proband and of his oligosympto- matic mother respectively. Nucleotide on September 27, 2021 by guest. Protected copyright. sequencing of the Istituto di Scienze mitochondrial Neurologiche, tRNAIeu(UUR) and tRNALYs in the proband's Universita di Siena, muscle failed to show any additional Italy nucleotide change which could account G M Fabrizi E Cardaioli for the clinical oddity of this pedigree by G S Grieco modulating the expression of the primary A Malandrini pathogenic mutation. L Manneschi M T Dotti Conclusion-So far, MERRF has been A Federico associated with mutations of the G Guazzi mitochondrial tRNALYS, and MELAS with Istituto di Neurologia, mutations of the mitochondrial Universita di Verona, tRNALeu(UuR). Now MERRF may also be Italy considered among the clinical syndromes T Cavallaro I Correspondence to: associated with the A to G transition at nt Dr G M Fabrizi, Istituto di 3243 of the tRNALeu(uuR). Scienze Neurologiche, Universiti di Siena, Viale Bracci, 53100 Siena, Italy. (7 Neurol Neurosurg Psychiatry 1996;61:45-5 1) Figure 1 Pedigree: black symbol indicates the severely Received 31 October 1995 affected proband; grey symbols indicate the and in final revised form oligosymptomatic members. Percentage of the mutated 19 February 1996 mtDNA in muscle is given as m; percentage ofthe mutated Accepted 23 February 1996 Keywords: MERRF; MELAS; mitochondrial DNA mtDNA in blood is given as b. 48 Fabrizi, Cardaioli, Grieco, Cavallaro, Malandrini, Manneschi, et al unsteadiness of gait and limb tremors. At the proic acid and phenobarbitone. At the age of age of 6, he was admitted for generalised 10, when the patient was evaluated by us, J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.61.1.47 on 1 July 1996. Downloaded from seizures; examination disclosed mental retar- weight and height were below the 100 per- dation, generalised ataxia, intentional tremor centile. His IQ was 62. An ECG showed a and diffuse muscle weakness, and hypotrophy. block of the right bundle branch; an echocar- An EEG showed bilateral irritative elements diogram was normal. There was generalised and generalised slow activity. An EMG had a muscle wasting, gait ataxia and dysmetria, myopathic pattern in the proximal limb mus- intention myoclonus, nystagmus, hyperreflexia cles. Brain CT showed bilateral calcifications of the lower limbs, bilateral optic atrophy, and of the basal ganglia and atrophy of the fron- cervical lipoma. An EEG showed synchronous totemporal cortical and subcortical regions (fig bursts of sharp waves and spike wave com- 2A). At the age of 7, generalised myoclonic plexes on the temporal regions. Audiometric jerks appeared, sometimes followed by grand tests disclosed neural deafness. Fundoscopy mal attacks; seizures were frequent (five- disclosed bilateral optic atrophy with a normal 10/day) and were partially responsive to val- electroretinogram. Proteins in CSF were 103 mg% with a normal IgG/albumin ratio. Abnormal laboratory investigations included Figure 2 (A) Proband's blood lactate (405 mg/dl, normal 2 7-11 7 CT (6 years of age) mg/dl), pyruvate (115 mg/dl, normal 026-07 showing calcifications of the lactate to pyruvate ratio. basal ganglia and atrophy mg/dl), and increased of the frontotemporal Parathyroid hormone (amino acids 1-84) was cortical and subcortical 29 pg/ml (normal range 5-10 pg/ml) and cal- regions. (B) proband's Ti caemia was 9-1 mg/dl. Brain MRI disclosed weighted MRI coronal section (18 years of age), diffuse supratentorial and infratentorial atro- showing a severe phy of the cortical and subcortical regions. supratentorial and The syndrome evolved towards a severe mental infratentorial cortical and subcortical atrophy. deterioration with spastic tetraparesis, dysarthria, dysphagia, and recurrent gener- alised myoclonic seizures. Brain MRI per- formed at the age of 18 showed a severe atrophy of the cerebral cortex and subcortical white matter, as well as of the semiovale cen- tres and corpus callosum. Cerebellar hemi- spheres and the vermis were also atrophic (fig 2B). Family member II-1: mother of the proband The mother of the proband, 43 years old, had a negative neurological history. Since the age of 30 she had had multinodular euthyroid goitre which was treated with thyroxine. Clinical examination disclosed a cervical lipoma. An http://jnnp.bmj.com/ EMG was normal. Among relevant laboratory investigations, blood lactate, pyruvate, T3, T4, thyroid stimulating hormone, and parathyroid hormone (amino acids 1-84) were in the normal ranges. Brain CT disclosed bilateral basal ganglia calcifications and atro- phy of the frontotemporal cortex, cerebellum, on September 27, 2021 by guest. Protected copyright. .:..i.. and pons. Ophthalmoscopy and audiometric 'A. tests normal results. "' gave Non-examined maternal members member rX The proband's grandmother, family I-1, aged 65, had had hyperthyroidism since the age of 25. At the age of 50 fluorangiogra- phy had shown bilateral drusen of the optic disc and degeneration of the macular epithe- lium of the left eye. The proband's sister, family member 111-2, 14 years old, had headache and nasal speech. 's^ MORPHOLOGICAL STUDIES The proband's biopsy specimens were obtained under local anaesthesia from the right deltoid muscle at the age of 10 and from the left vastus lateralis muscle at the age of 18; a biopsy of the deltoid muscle was also per- formed in the 43 year old mother. Specimens for histopathological study were frozen in The A to G transition at nt 3243 of the mitochondrial tRNA'-LtU-RI may cause a MERRF syndrome 49 Figure 3 Modified Gomori trichrome stain *\.\t J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.61.1.47 on 1 July 1996. Downloaded from (A x 140) and cytochrome c oxidase .. ,.. 0. ,.V, te,. 0.s_ ,*;v :. _ reaction (B x 140) in the *X.,.)iM--_ 4 * wit;;ie. ¢/e'; mother's deltoid mnuscle; asterisks indicate the faU' correspondingfibres in serial sections. Ragged red %;r A. fibres have a strong lp 0 ...:A,, cytochrome c oxidase activity which is more .E I '. Or_).;8 intense at the periphery. I (C) Succinate * <t8;2.'.,r dehydrogenase stainling on the proband's second muscle biopsy (x 175) shows a small artery with densely stained granules in its wall. t ;A_;S.+X9. / (D) Electronmicrography I X,ttt; 0S of the proband's second mtiuscle biopsy, shows aggregates 4 A; i 4\$S ! ! of ;i i.ntermyofibrillar .j.l, mitochondria containing paracrystalline inclusions ( x 4200). http://jnnp.bmj.com/ isopentane cooled with liquid nitrogen. Serial MOLECULAR GENETIC ANALYSIS 8 pum thick transverse sections were stained Total DNA was extracted from blood of family with haematoxylin and eosin, modified members III-1, II-1, and I-1 and from 50 mg Gomori trichrome, and a battery of histo- of frozen bioptic muscle of members III-1 and chemical methods including succinate dehy- II-1, according to standard procedures. The drogenase, routine ATPase, ATPase with presence of the following pathogenic point preincubation at pH 4,6 and 43, and mutations of mtDNA were investigated on the on September 27, 2021 by guest. Protected copyright. cytochrome c oxidase. Small pieces of the proband's muscle mtDNA, by standard specimens were fixed in 2-5% glutaraldehyde RFLP-PCR (polymerase chain reaction) and postfixed in 1% 0S04 in 01- M phosphate analysis: MERRF A8344G and T8356C at buffer.
Recommended publications
  • Cardiac Manifestations in Emery–Dreifuss Muscular Dystrophy
    PRACTICE | CASES CPD Cardiac manifestations in Emery–Dreifuss muscular dystrophy Whitney Faiella MD, Ricardo Bessoudo MD n Cite as: CMAJ 2018 December 3;190:E1414-7. doi: 10.1503/cmaj.180410 35-year-old man with a known history of Emery–Dreifuss muscular dystrophy called emergency medical services KEY POINTS (EMS) while at work one morning, reporting palpitations, • Emery–Dreifuss muscular dystrophy is one of many lightheadedness,A fatigue and a rapid heart rate. On arrival by neuromuscular diseases with cardiac involvement, including EMS, his pulse was documented at 195–200 beats/min, and his bradyarrhythmia, tachyarrhythmia and cardiomyopathy, and rhythm strips showed ventricular tachycardia (Figure 1A). He involves an increased risk of sudden cardiac death. underwent cardioversion and was given a bolus of amiodarone, • A recently published scientific statement highlights key cardiac 150 mg intravenously. In the emergency department and during manifestations in various forms of neuromuscular diseases and includes detailed recommendations regarding screening, admission, his symptoms persisted with rhythm strips showing follow-up and treatment for each individual disease. recurrent episodes of sustained ventricular tachycardia (Fig- • Medical optimization of cardiac function and early detection of ure 1B). He was subsequently started on an amiodarone drip and arrhythmias with subsequent insertion of a pacemaker or oral metoprolol. Echocardiography performed during admission defibrillator can be life-saving in this patient population. showed dilated cardiomyopathy with severe systolic dysfunction and an estimated ejection fraction of 23%. Cardiac catheteriza- tion was performed to rule out an ischemic cause of the cardio- With respect to the patient’s diagnosis of Emery–Dreifuss mus- myopathy and showed normal coronary arteries.
    [Show full text]
  • When Should MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic
    DOI: 10.1590/0004-282X20150154 VIEW ANDARTICLE REVIEW When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis? Quando o diagnóstico deveria ser MELAS (Miopatia mitocondrial, encefalopatia, acidose lática, e episódios semelhantes a acidente vascular cerebral)? Paulo José Lorenzoni, Lineu Cesar Werneck, Cláudia Suemi Kamoi Kay, Carlos Eduardo Soares Silvado, Rosana Herminia Scola ABSTRACT Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a rare mitochondrial disorder. Diagnostic criteria for MELAS include typical manifestations of the disease: stroke-like episodes, encephalopathy, evidence of mitochondrial dysfunction (laboratorial or histological) and known mitochondrial DNA gene mutations. Clinical features of MELAS are not necessarily uniform in the early stages of the disease, and correlations between clinical manifestations and physiopathology have not been fully elucidated. It is estimated that point mutations in the tRNALeu(UUR) gene of the DNAmt, mainly A3243G, are responsible for more of 80% of MELAS cases. Morphological changes seen upon muscle biopsy in MELAS include a substantive proportion of ragged red fibers (RRF) and the presence of vessels with a strong reaction for succinate dehydrogenase. In this review, we discuss mainly diagnostic criterion, clinical and laboratory manifestations, brain images, histology and molecular findings as well as some differential diagnoses and current treatments. Keywords: MELAS, mitochondria, myopathy, stroke, encephalopathy, genetics. RESUMO Miopatia mitocondrial, encefalopatia, acidose lática, e episódios semelhantes a acidente vascular cerebral (MELAS) é uma rara doença mitocondrial. Os critérios diagnósticos para MELAS incluem as manifestações típicas da doença: episódios semelhantes a acidente vascular cerebral, encefalopatia, evidência de disfunção mitocondrial (laboratorial ou histológica) e mutação conhecida em genes do DNA mitocondrial.
    [Show full text]
  • Multiple Presentation of Mitochondrial Disorders Arch Dis Child: First Published As 10.1136/Adc.81.3.209 on 1 September 1999
    Arch Dis Child 1999;81:209–215 209 Multiple presentation of mitochondrial disorders Arch Dis Child: first published as 10.1136/adc.81.3.209 on 1 September 1999. Downloaded from Andreea Nissenkorn, Avraham Zeharia, Dorit Lev, Aviva Fatal-Valevski, Varda Barash, Alisa Gutman, Shaul Harel, Tally Lerman-Sagie Abstract The most severely aVected organs in mito- The aim of this study was to assess the chondrial disorders are those depending on heterogeneous clinical presentations of high rate aerobic metabolism—for example, children with mitochondrial disorders the brain, skeletal and cardiac muscle, the sen- evaluated at a metabolic neurogenetic sory organs, and the kidney.125 We aimed to clinic. The charts of 36 children with describe the great variety of symptomatology in highly suspected mitochondrial disorders patients with mitochondrial disorders in Israel, were reviewed. Thirty one children were and to compare this with the common clinical diagnosed as having a mitochondrial dis- presentations in other countries. order, based on a suggestive clinical pres- entation and at least one of the accepted Patients and methods laboratory criteria; however, in five chil- Thirty six consecutive patients (20 boys and 16 dren with no laboratory criteria the diag- girls) were evaluated at the paediatric neurol- nosis remained probable. All of the ogy clinic, Dana Children’s Hospital from patients had nervous system involvement. August 1994 to August 1996 and at the meta- Twenty seven patients also had dysfunc- bolic neurogenetic clinic, Wolfson Medical tion of other systems: sensory organs in 15 Center from September 1996 to June 1998 for patients, cardiovascular system in five, suspected mitochondrial disorders.
    [Show full text]
  • Progressive Myoclonic Epilepsy
    www.neurologyindia.com Indian Perspective Progressive myoclonic epilepsy P. Satishchandra, S. Sinha Department of Neurology, National Institute of Mental Health & Neurosciences, Bangalore, India Abstract Progressive myoclonic epilepsy (PME) is a disease complex and is characterized by the development of relentlessly progressive myoclonus, cognitive impairment, ataxia, and other neurologic deficits. It encompasses different diagnostic entities and the common causes include Lafora body disease, neuronal ceroid lipofuscinoses, Unverricht–Lundborg disease, myoclonic epilepsy with ragged-red fiber (MERRF) syndrome, sialidoses, dentato-rubro-pallidal atrophy, storage diseases, and some of the inborn errors of metabolism, among others. Recent advances in this area have clarified molecular genetic basis, biological basis, and natural history, and also provided Address for correspondence: a rational approach to the diagnosis. Most of the large studies related to PME are from Dr. P. Satishchandra, south India from a single center, National Institute of Mental Health and Neurological National Institute of Mental Health Sciences (NIMHANS), Bangalore. However, there are a few case reports and small series & Neurosciences (NIMHANS), Hosur Road, Bangalore - 560 029, about Lafora body disease, neuronal ceroid lipofuscinoses and MERRF from India. We India. review the clinical and research experience of a cohort of PME patients evaluated at E-mail: drpsatishchandra@yahoo. NIMHANS over the last two decades, especially the phenotypic, electrophysiologic,
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • Neuromuscular Disorders Neurology in Practice: Series Editors: Robert A
    Neuromuscular Disorders neurology in practice: series editors: robert a. gross, department of neurology, university of rochester medical center, rochester, ny, usa jonathan w. mink, department of neurology, university of rochester medical center,rochester, ny, usa Neuromuscular Disorders edited by Rabi N. Tawil, MD Professor of Neurology University of Rochester Medical Center Rochester, NY, USA Shannon Venance, MD, PhD, FRCPCP Associate Professor of Neurology The University of Western Ontario London, Ontario, Canada A John Wiley & Sons, Ltd., Publication This edition fi rst published 2011, ® 2011 by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Hereditary Muscle Diseases and the Heart: the Cardiologist's Perspective
    European Heart Journal Supplements (2020) 22 (Supplement E), E13–E19 The Heart of the Matter doi:10.1093/eurheartj/suaa051 Hereditary muscle diseases and the heart: the cardiologist’s perspective Lorenzo Giuliani1, Alessandro Di Toro1, Mario Urtis1, Alexandra Smirnova1, Monica Concardi1, Valentina Favalli2, Alessandra Serio1, Maurizia Grasso1, and Eloisa Arbustini1* 1Centre for Inherited Cardiovascular Diseases, IRCCS Foundation University Hospital Policlinico San Matteo, Pavia, Italy; and 2Ingenomics Srls, Polo Tecnologico, Pavia, Italy KEYWORDS Hereditary muscle disease; Cardiomyopathy; Heart failure Introduction patients in a way to collect data useful in accelerating tar- geted treatment development. Cardiac manifestations in hereditary muscle diseases in- clude cardiomyopathies, defects of cardiac conductions Dilated and hypokinetic phenotypes (DCM) with or without primary myocardial muscle involvement, 1,2 and arrhythmias. Symptoms and signs of these diseases The most common heritable muscle diseases affecting the 3 may exhibit in paediatric as well as in adult age, and in heart and leading to dilated and hypokinetic cardiac phe- many cases only a multidisciplinary clinical approach can notype include dystrophinopathies, limb girdle muscular 4,5 ensure correct diagnosis and management. Cardiologists dystrophies (LGMD), and Emery–Dreifuss Muscular might be the first to recognize an apparently lone cardiac Dystrophies (EDMD). involvement as an important clinical marker of an heredi- tary muscle disease or be the first in line in a multidiscipli- nary team when cardiac involvement represents the major Dystrophinopathies clinical manifestation affecting evolution and prognosis of Mutations in the DMD gene encoding for dystrophin cause the disease.6 dystrophinopathies, a group of rare X-linked recessive The actual classifications of hereditary muscle disorders (XLR) muscle diseases.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Haematological Abnormalities in Mitochondrial Disorders
    Singapore Med J 2015; 56(7): 412-419 Original Article doi: 10.11622/smedj.2015112 Haematological abnormalities in mitochondrial disorders Josef Finsterer1, MD, PhD, Marlies Frank2, MD INTRODUCTION This study aimed to assess the kind of haematological abnormalities that are present in patients with mitochondrial disorders (MIDs) and the frequency of their occurrence. METHODS The blood cell counts of a cohort of patients with syndromic and non-syndromic MIDs were retrospectively reviewed. MIDs were classified as ‘definite’, ‘probable’ or ‘possible’ according to clinical presentation, instrumental findings, immunohistological findings on muscle biopsy, biochemical abnormalities of the respiratory chain and/or the results of genetic studies. Patients who had medical conditions other than MID that account for the haematological abnormalities were excluded. RESULTS A total of 46 patients (‘definite’ = 5; ‘probable’ = 9; ‘possible’ = 32) had haematological abnormalities attributable to MIDs. The most frequent haematological abnormality in patients with MIDs was anaemia. 27 patients had anaemia as their sole haematological problem. Anaemia was associated with thrombopenia (n = 4), thrombocytosis (n = 2), leucopenia (n = 2), and eosinophilia (n = 1). Anaemia was hypochromic and normocytic in 27 patients, hypochromic and microcytic in six patients, hyperchromic and macrocytic in two patients, and normochromic and microcytic in one patient. Among the 46 patients with a mitochondrial haematological abnormality, 78.3% had anaemia, 13.0% had thrombopenia, 8.7% had leucopenia and 8.7% had eosinophilia, alone or in combination with other haematological abnormalities. CONCLUSION MID should be considered if a patient’s abnormal blood cell counts (particularly those associated with anaemia, thrombopenia, leucopenia or eosinophilia) cannot be explained by established causes.
    [Show full text]
  • Myoclonus Epilepsy Associated with Ragged-Red Fibers
    DOI: 10.1590/0004-282X20140124 VIEWS AND REVIEWS When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis? Quando o diagnóstico deveria ser MERRF (epilepsia mioclônica associada com fibras vermelhas rasgadas)? Paulo José Lorenzoni, Rosana Herminia Scola, Cláudia Suemi Kamoi Kay, Carlos Eduardo S. Silvado, Lineu Cesar Werneck ABSTRACT Myoclonic epilepsy associated with ragged red fibers (MERRF) is a rare mitochondrial disorder. Diagnostic criteria for MERRF include typical manifestations of the disease: myoclonus, generalized epilepsy, cerebellar ataxia and ragged red fibers (RRF) on muscle biopsy. Clinical features of MERRF are not necessarily uniform in the early stages of the disease, and correlations between clinical manifestations and physiopathology have not been fully elucidated. It is estimated that point mutations in the tRNALys gene of the DNAmt, mainly A8344G, are responsible for almost 90% of MERRF cases. Morphological changes seen upon muscle biopsy in MERRF include a substantive proportion of RRF, muscle fibers showing a deficient activity of cytochrome c oxidase (COX) and the presence of vessels with a strong reaction for succinate dehydrogenase and COX deficiency. In this review, we discuss mainly clinical and laboratory manifestations, brain images, electrophysiological patterns, histology and molecular findings as well as some differential diagnoses and treatments. Keywords: MERRF, mitochondrial, epilepsy, myoclonus, myopathy. RESUMO Epilepsia mioclônica associada com fibras vermelhas rasgadas (MERRF) é uma rara doença mitocondrial. O critério diagnóstico para MERRF inclui as manifestações típicas da doença: mioclonia, epilepsia generalizada, ataxia cerebelar e fibras vermelhas rasgadas (RRF) na biópsia de músculo. Na fase inicial da doença, as manifestações clínicas podem não ser uniformes, e correlação entre as manifestações clínicas e fisiopatologia não estão completamente elucidadas.
    [Show full text]
  • Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders
    Supplementary Online Content Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. doi:10.1001/jama.2014.14604. eMethods 1. Sample acquisition and pre-test sample processing eMethods 2. Exome capture and sequencing eMethods 3. Sequence data analysis eMethods 4. Variant filtration and interpretation eMethods 5. Determination of variant pathogenicity eFigure 1. UCLA Clinical Exome Sequencing (CES) workflow eFigure 2. Variant filtration workflow starting with ~21K variants across the exome and comparing the mean number of variants observed from trio-CES versus proband-CES eFigure 3. Variant classification workflow for the variants found within the primary genelist (PGL) eTable 1. Metrics used to determine the adequate quality of the sequencing test for each sample eTable 2. List of molecular diagnoses made eTable 3. List of copy number variants (CNVs) and uniparental disomy (UPD) reported and confirmatory status eTable 4. Demographic summary of 814 cases eTable 5. Molecular Diagnosis Rate of Phenotypic Subgroups by Age Group for Other Clinical Exome Sequencing References © 2014 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 This supplementary material has been provided by the authors to give readers additional information about their work. © 2014 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eMethods 1. Sample acquisition and pre-test sample processing. Once determined by the ordering physician that the patient's presentation is clinically appropriate for CES, patients were offered the test after a counseling session ("pre-test counseling") [eFigure 1].
    [Show full text]
  • Adult-Onset Mitochondrial Myopathy J
    Postgrad Med J: first published as 10.1136/pgmj.68.797.212 on 1 March 1992. Downloaded from Postgrad Med J (1992) 68, 212 - 215 © The Fellowship of Postgraduate Medicine, 1992 Adult-onset mitochondrial myopathy J. Fernandez-Sola, J. Casademont, J.M. Grau, F. Graus', F. Cardellach, E. Pedrol and A. Urbano-Marquez Muscle Research Group, Internal Medicine Service, and 'Department ofNeurology, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain Summary: Mitochondrial diseases are polymorphic entities which may affect many organs and systems. Skeletal muscle involvement is frequent in the context of systemic mitochondrial disease, but adult-onset pure mitochondrial myopathy appears to be rare. We report 3 patients with progressive skeletal mitochondrial myopathy starting in adult age. In all cases, the proximal myopathy was the only clinical feature. Mitochondrial pathology was confirmed by evidence of ragged-red fibres in muscle histochemistry, an abnormal mitochondrial morphology in electron microscopy and by exclusion of other underlying diseases. No deletions of mitochondrial DNA were found. We emphasize the need to look for a mitochondrial disorder in some non-specific myopathies starting in adult life. Introduction Mitochondrial diseases consist ofvarious polymor- These patients usually have proximal muscleby copyright. phic pathological entities which usually involve weakness and myalgia. Muscle atrophy of the many organs and systems. They represent a wide affected areas is frequent. The whole clinical pic- clinical, pathological and biochemical spectrum.' ture is not specific and there is a wide differential Involvement ofskeletal and ocular muscles, central diagnosis including inflammatory, toxic, neoplas- and peripheral nervous system, liver, heart, blood tic, metabolic and endocrine myopathies.
    [Show full text]